ClinicalTrials.gg
Active, not recruitingNCT04191499INAVO120Updated Sep 11, 2026Results posted

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

A Phase 2/3 interventional study of Inavolisib and Placebo in Breast Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 135 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Hoffmann-La Roche · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing inavolisib in Breast Neoplasms — 12 open to participants now, 15 under way, 4 of them phase 3. inavolisib · Breast Neoplasms.

Enrollment
5th of 16
325 · median 185
Started
2020
the only one that year
Phase 2/3
Only one
of the 16
Primary completion
2023-09
later than 0 of 14 live
Registered
3rd of 16
by date
Lead sponsor
9 of 16
Hoffmann-La Roche

Among the 16 studies testing inavolisib in Breast Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2020, is the only one in phase 2/3, reaches primary completion later than 0 of the 14 other live ones, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 16 studies testing inavolisib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About inavolisib

inavolisib: first FDA approval 2024 (ITOVEBI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inavolisib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in participants with PIK3CA-mutant, hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant endocrine therapy and who have not received prior systemic therapy for metastatic disease.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of HR+/- breast cancer
  • or locally advanced disease not amenable to curative therapy
  • Progression of disease during endocrine treatment or within 12 months of completing adjuvant endocrine therapy with an aromatase inhibitor or tamoxifen
  • Receiving LHRH agonist therapy for at least 2 weeks prior to Day 1 of Cycle 1 if pre/peri-menopausal
  • Confirmation of biomarker eligibility (detection of specified mutation(s) of PIK3CA via specified test)
  • Consent to provide fresh or specimen
  • per , Version 1.1 (RECIST v1.1); evaluable "bone-only" disease is not eligible; "bone-only" disease with at least one measurable, soft-tissue component, even if considered disease that is limited to bone but has lytic or mixed lytic/blastic lesions and at least one measurable soft-tissue component per RECIST v1.1 may be eligible
  • Performance Status of 0 or 1
  • of > 6 months
  • Adequate hematologic and organ function within 14 days prior to initiation of study treatment

Exclusion criteria

Exclusion Criteria

  • Metaplastic breast cancer
  • Any history of or carcinomatous meningitis
  • Any prior systemic therapy for breast cancer
  • Prior treatment with fulvestrant or any selective estrogen-receptor degrader, with the exception of participants that have received fulvestrant or any selective estrogen-receptor degrader as part of therapy only and with treatment duration of no longer than 6 months
  • Prior treatment with any PI3K, AKT, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway
  • Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
  • Known and untreated, or active . Patients with a history of treated CNS metastases may be eligible
  • Active inflammatory or infectious conditions in either eye, or any eye conditions expected to require surgery during the study treatment period
  • Symptomatic active lung disease, or requiring daily supplemental oxygen
  • History of inflammatory bowel disease or active bowel inflammation
  • Anti-cancer therapy within 2 weeks before study entry
  • drug(s) within 4 weeks before randomization
  • Prior radiotherapy to >= 25% of bone marrow, or hematopoietic stem cell or bone marrow transplantation
  • Chronic therapy or
  • Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or within 2 weeks after the final dose of study treatment
  • Major surgical procedure, or significant traumatic injury, within 28 days prior to Day 1 of Cycle 1
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    Inavolisib + Palbociclib + Fulvestrant

    Participants will receive inavolisib, palbociclib, and fulvestrant.

    Drug: Inavolisib · Drug: Palbociclib · Drug: Fulvestrant

  • Placebo comparator
    Placebo + Palbociclib + Fulvestrant

    Participants will receive placebo, palbociclib, and fulvestrant. Participants randomized to the placebo arm who are still deriving benefit from the study treatment will be given an optional opportunity to crossover to the inavolisib arm.

    Drug: Placebo · Drug: Palbociclib · Drug: Fulvestrant

Interventions

  • Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.

    Also known as: GDC-0077

  • DrugPlacebo

    Participants will receive oral placebo on Days 1-28 of each 28-day cycle.

  • Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.

  • Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 or death from any cause (whichever occurs first). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression. Data for participants without the occurrence of PD or death as of the clinical cutoff date (CCOD) were censored at the time of the last tumor assessment prior to the CCOD. Median PFS was calculated using the Kaplan-Meier methodology.

    Time frame: Up to 3.7 years

Secondary outcomes

  1. Percentage of Participants With Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with a complete response (CR) and/or partial response (PR) on at least two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR is defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline.

    Time frame: Up to approximately 6 years

  2. Percentage of Participants With Best Overall Response Rate (BOR)

    BOR is defined as the percentage of participants with a CR or PR, as determined by the investigator according to RECIST v1.1. CR is defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline.

    Time frame: Up to approximately 6 years

  3. Duration of Response (DOR)

    DOR is defined as the time from the first occurrence of a CR or PR to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1, or death from any cause (whichever occurs first). CR is defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

    Time frame: Up to approximately 6 years

  4. Percentage of Participants With Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants with a CR, PR, and/or stable disease (SD) for at least 24 weeks, as determined by the investigator according to RECIST v1.1. CR= disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum in the study.

    Time frame: Up to approximately 6 years

  5. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: Up to approximately 6 years

  6. Time to Deterioration (TTD) in Pain

    TTD in pain is defined as the time from randomization to the first documentation of a ≥ 2-point increase from baseline on the "worst pain" item from the Brief Pain Inventory-Short Form (BPI-SF). BPI-SF is a self-administered questionnaire in which the participant was asked to rate severity on a 10-point scale where 0 represents 'No pain/No interference' and 10 represents 'Pain/Interference as bad as you can imagine'. A ≥2-point change is defined as clinically meaningful difference.

    Time frame: From randomization to first documentation of a ≥ 2-point increase (Up to approximately 6 years)

  7. TTD in Physical Function (PF)

    TTD in physical function is defined as the time from randomization to the first documentation of a ≥ 10-point decrease from baseline held for two consecutive cycles or initial decrease followed by death or treatment discontinuation within three weeks of last assessment in the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) PF scale (items 1-5). A ≥10-point change is defined as a clinically meaningful difference. EORTC QLQ-C30 is a cancer-specific health-related quality-of life (QoL) questionnaire with 30 questions. For the PF scale, participant responses to 5 questions about daily activities (strenuous activities, long walks, short walks, bed/chair rest \& needing help with eating, dressing, washing themselves, or using the toilet) is scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating worst functioning.

    Time frame: Treatment: Day 1 of Cycles 1-3, then Day 1 of every other cycle until treatment discontinuation. Post-treatment: Every 8 weeks for 2 years, then every 12 weeks thereafter, to end of study (up to 6 years) (Cycle length = 28 days)]

  8. TTD in Role Function (RF)

    TTD in Role Function is defined as the time from randomization to the first documentation of a ≥ 10-point decrease from baseline held for two consecutive cycles, or initial decrease followed by death or treatment discontinuation within three weeks of last assessment in the EORTC QLQ-C30 RF scale (items 6 and 7). A ≥10-point change is defined as clinically meaningful difference. EORTC QLQ-C30 is a cancer specific health-related QoL questionnaire. For the role functioning scale, participant responses to the 2 questions "Q6: Were you limited in doing either your work or daily activities" and "Q7: Were you limited in pursuing your hobbies or other leisure time activities" were scored on a 4-point scale (1=Not at All to 4=Very Much). The scores were linearly transformed on a scale of 0 to 100, with a low score indicating better functioning.

    Time frame: Treatment: Day 1 of Cycles 1-3, then Day 1 of every other cycle until treatment discontinuation. Post-treatment: Every 8 weeks for 2 years, then every 12 weeks thereafter, to end of study (up to 6 years) (Cycle length = 28 days)]

  9. TTD in Global Health Status (GHS)

    TTD in (GHS)/health-related quality of life (HRQoL) is defined as the time from randomization to the first documentation of a ≥ 10-point decrease from baseline held for two consecutive cycles, or initial decrease followed by death or treatment discontinuation within three weeks of last assessment in the EORTC QLQ-30 GHS/HRQoL scale. A ≥10-point change is defined as clinically meaningful difference. EORTC QLQ-C30 is a cancer specific health-related QoL questionnaire. Participant responses to the questions regarding Global Health Status (Q29: GHS; "How would you rate your overall health during the past week?") and Quality of Life (Q30: QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better outcome.

    Time frame: Treatment: Day 1 of Cycles 1-3, then Day 1 of every other cycle until treatment discontinuation. Post-treatment: Every 8 weeks for 2 years, then every 12 weeks thereafter, to end of study (up to 6 years) (Cycle length = 28 days)]

  10. Number of Participants With Adverse Events (AEs)

    An AE is an untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product.

    Time frame: Up to approximately 6 years

  11. Plasma Concentration of Inavolisib

    Time frame: Predose on Cycle 1 Days 1, 8 and 15 and Cycle 2 Day 15; 3 hours post-dose on Cycle 1 Days 1 and 15 (Cycle length = 28 days)

  12. Plasma Concentration of Palbociclib

    Time frame: Predose on Cycle 1 Days 1, 8 and 15 and Cycle 2 Day 15; 3 hours post-dose on Cycle 1 Days 1 and 15 (Cycle length = 28 days)

  13. Plasma Concentration of Fulvestrant

    Time frame: Predose on Cycle 1 Days 1, 8 and 15 and Cycle 2 Day 15; 3 hours post-dose on Cycle 1 Days 1 and 15 (Cycle length = 28 days)

07

Results

Posted Oct 9, 2024

Participant flow

Participants took part in the study across 123 investigative centers in 28 countries. This study is still ongoing.

Participant flow — Overall Study
MilestoneInavo+Palbo+FulvPbo+Palbo+Fulv
Started161164
Completed00
Not completed161164
Withdrew: Adverse event10
Withdrew: Death4255
Withdrew: Lost to follow-up41
Withdrew: Physician decision10
Withdrew: Progressive disease10
Withdrew: Symptomatic deterioration10
Withdrew: Withdrawal by subject711
Withdrew: Ongoing in the study10497

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 or death from any cause (whichever occurs first). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression. Data for participants without the occurrence of PD or death as of the clinical cutoff date (CCOD) were censored at the time of the last tumor assessment prior to the CCOD. Median PFS was calculated using the Kaplan-Meier methodology.

Time frame:
Up to 3.7 years
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsInavo+Palbo+FulvPbo+Palbo+Fulv
Progression-Free Survival (PFS)15 (11.3 to 20.5)7.3 (5.6 to 9.3)
Statistical analysis
  • Inavo+Palbo+Fulv vs Pbo+Palbo+Fulv · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.43 · 95% CI 0.32 to 0.59
SecondaryPercentage of Participants With Objective Response Rate (ORR)

ORR is defined as the percentage of participants with a complete response (CR) and/or partial response (PR) on at least two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR is defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Best Overall Response Rate (BOR)

BOR is defined as the percentage of participants with a CR or PR, as determined by the investigator according to RECIST v1.1. CR is defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR)

DOR is defined as the time from the first occurrence of a CR or PR to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1, or death from any cause (whichever occurs first). CR is defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Clinical Benefit Rate (CBR)

CBR is defined as the percentage of participants with a CR, PR, and/or stable disease (SD) for at least 24 weeks, as determined by the investigator according to RECIST v1.1. CR= disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum in the study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum in the study.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS is defined as the time from randomization to death from any cause.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryTime to Deterioration (TTD) in Pain

TTD in pain is defined as the time from randomization to the first documentation of a ≥ 2-point increase from baseline on the "worst pain" item from the Brief Pain Inventory-Short Form (BPI-SF). BPI-SF is a self-administered questionnaire in which the participant was asked to rate severity on a 10-point scale where 0 represents 'No pain/No interference' and 10 represents 'Pain/Interference as bad as you can imagine'. A ≥2-point change is defined as clinically meaningful difference.

Time frame:
From randomization to first documentation of a ≥ 2-point increase (Up to approximately 6 years)

Results for this outcome have not been posted.

SecondaryTTD in Physical Function (PF)

TTD in physical function is defined as the time from randomization to the first documentation of a ≥ 10-point decrease from baseline held for two consecutive cycles or initial decrease followed by death or treatment discontinuation within three weeks of last assessment in the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) PF scale (items 1-5). A ≥10-point change is defined as a clinically meaningful difference. EORTC QLQ-C30 is a cancer-specific health-related quality-of life (QoL) questionnaire with 30 questions. For the PF scale, participant responses to 5 questions about daily activities (strenuous activities, long walks, short walks, bed/chair rest \& needing help with eating, dressing, washing themselves, or using the toilet) is scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating worst functioning.

Time frame:
Treatment: Day 1 of Cycles 1-3, then Day 1 of every other cycle until treatment discontinuation. Post-treatment: Every 8 weeks for 2 years, then every 12 weeks thereafter, to end of study (up to 6 years) (Cycle length = 28 days)]

Results for this outcome have not been posted.

SecondaryTTD in Role Function (RF)

TTD in Role Function is defined as the time from randomization to the first documentation of a ≥ 10-point decrease from baseline held for two consecutive cycles, or initial decrease followed by death or treatment discontinuation within three weeks of last assessment in the EORTC QLQ-C30 RF scale (items 6 and 7). A ≥10-point change is defined as clinically meaningful difference. EORTC QLQ-C30 is a cancer specific health-related QoL questionnaire. For the role functioning scale, participant responses to the 2 questions "Q6: Were you limited in doing either your work or daily activities" and "Q7: Were you limited in pursuing your hobbies or other leisure time activities" were scored on a 4-point scale (1=Not at All to 4=Very Much). The scores were linearly transformed on a scale of 0 to 100, with a low score indicating better functioning.

Time frame:
Treatment: Day 1 of Cycles 1-3, then Day 1 of every other cycle until treatment discontinuation. Post-treatment: Every 8 weeks for 2 years, then every 12 weeks thereafter, to end of study (up to 6 years) (Cycle length = 28 days)]

Results for this outcome have not been posted.

SecondaryTTD in Global Health Status (GHS)

TTD in (GHS)/health-related quality of life (HRQoL) is defined as the time from randomization to the first documentation of a ≥ 10-point decrease from baseline held for two consecutive cycles, or initial decrease followed by death or treatment discontinuation within three weeks of last assessment in the EORTC QLQ-30 GHS/HRQoL scale. A ≥10-point change is defined as clinically meaningful difference. EORTC QLQ-C30 is a cancer specific health-related QoL questionnaire. Participant responses to the questions regarding Global Health Status (Q29: GHS; "How would you rate your overall health during the past week?") and Quality of Life (Q30: QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better outcome.

Time frame:
Treatment: Day 1 of Cycles 1-3, then Day 1 of every other cycle until treatment discontinuation. Post-treatment: Every 8 weeks for 2 years, then every 12 weeks thereafter, to end of study (up to 6 years) (Cycle length = 28 days)]

Results for this outcome have not been posted.

SecondaryNumber of Participants With Adverse Events (AEs)

An AE is an untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product.

Time frame:
Up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPlasma Concentration of Inavolisib
Time frame:
Predose on Cycle 1 Days 1, 8 and 15 and Cycle 2 Day 15; 3 hours post-dose on Cycle 1 Days 1 and 15 (Cycle length = 28 days)
Reported as:
Geometric mean · nanogram/milliliter (ng/ml)
Plasma Concentration of Inavolisib
nanogram/milliliter (ng/ml)Inavo+Palbo+Fulv
Predose, Cycle 1 Day 1NA ± NA
3 hours Post-dose, Cycle 1 Day 136 ± 223
Predose, Cycle 1 Day 817.8 ± 134
Predose, Cycle 1 Day 1513.6 ± 240
3 hours Post-dose, Cycle 1 Day 1559.2 ± 119
Predose, Cycle 2 Day 1516.9 ± 124
SecondaryPlasma Concentration of Palbociclib
Time frame:
Predose on Cycle 1 Days 1, 8 and 15 and Cycle 2 Day 15; 3 hours post-dose on Cycle 1 Days 1 and 15 (Cycle length = 28 days)
Reported as:
Geometric mean · ng/ml
Plasma Concentration of Palbociclib
ng/mlInavo+Palbo+FulvPbo+Palbo+Fulv
Predose, Cycle 1 Day 1NA ± NANA ± NA
3 hours Post-dose, Cycle 1 Day 120.7 ± 18222.9 ± 251
Predose, Cycle 1 Day 873.9 ± 5674.5 ± 50
Predose, Cycle 1 Day 1569.9 ± 7873.3 ± 65
3 hours Post-dose, Cycle 1 Day 1596.7 ± 5598.0 ± 62
Predose, Cycle 2 Day 1558.5 ± 11166.9 ± 90
SecondaryPlasma Concentration of Fulvestrant
Time frame:
Predose on Cycle 1 Days 1, 8 and 15 and Cycle 2 Day 15; 3 hours post-dose on Cycle 1 Days 1 and 15 (Cycle length = 28 days)
Reported as:
Geometric mean · ng/ml
Plasma Concentration of Fulvestrant
ng/mlInavo+Palbo+FulvPbo+Palbo+Fulv
Predose, Cycle 1 Day 1NA ± NANA ± NA
3 hours Post-dose, Cycle 1 Day 11.03 ± 2000.815 ± 200
Predose, Cycle 1 Day 817.5 ± 4616.2 ± 46
Predose, Cycle 1 Day 1511.9 ± 3710.9 ± 42
3 hours Post-dose, Cycle 1 Day 1512.2 ± 4411.1 ± 43
Predose, Cycle 2 Day 1518.0 ± 3717.3 ± 37

Adverse events

Collected over Up to 3.7 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inavo+Palbo+Fulv43/162 (26.5%)39/162 (24.1%)157/162 (96.9%)
Pbo+Palbo+Fulv54/162 (33.3%)17/162 (10.5%)158/162 (97.5%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventInavo+Palbo+FulvPbo+Palbo+Fulv
COVID-19Infections and infestations4/1621/162
AnaemiaBlood and lymphatic system disorders3/1620/162
Febrile neutropeniaBlood and lymphatic system disorders3/1620/162
PneumoniaInfections and infestations3/1620/162
Acute coronary syndromeCardiac disorders2/1620/162
DiarrhoeaGastrointestinal disorders2/1620/162
VomitingGastrointestinal disorders1/1622/162
PyrexiaGeneral disorders2/1620/162
Urinary tract infectionInfections and infestations2/1620/162
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1622/162
Most frequent other events
Showing 10 of 52
Most frequent other events
EventInavo+Palbo+FulvPbo+Palbo+Fulv
NeutropeniaBlood and lymphatic system disorders88/16289/162
HyperglycaemiaMetabolism and nutrition disorders87/16212/162
DiarrhoeaGastrointestinal disorders78/16226/162
Neutrophil count decreasedInvestigations63/16264/162
AnaemiaBlood and lymphatic system disorders58/16259/162
StomatitisGastrointestinal disorders53/16227/162
NauseaGastrointestinal disorders44/16227/162
Platelet count decreasedInvestigations42/16235/162
ThrombocytopeniaBlood and lymphatic system disorders36/16241/162
LeukopeniaBlood and lymphatic system disorders28/16240/162

Baseline characteristics

Full analysis set (FAS) included all participants who were randomized to receive the treatment they were assigned.

Age, Continuous
Age, Continuous(years)Inavo+Palbo+FulvPbo+Palbo+FulvTotal
Mean53.8 ± 10.954.1 ± 11.254.0 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Inavo+Palbo+FulvPbo+Palbo+FulvTotal
Female156163319
Male516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inavo+Palbo+FulvPbo+Palbo+FulvTotal
Hispanic or Latino101020
Not Hispanic or Latino145149294
Unknown or Not Reported6511
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Inavo+Palbo+FulvPbo+Palbo+FulvTotal
American Indian or Alaska Native000
Asian6163124
Native Hawaiian or Other Pacific Islander000
Black or African American112
White9497191
More than one race000
Unknown or Not Reported538
08

Study locations

135 sites

Showing the first 100 of 135 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, Loi S, Thanopoulou E, Shankar N, Jin Y, Stout TJ, Clark TD, Song C, Juric D, Turner NC. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Jul 10;393(2):151-161. doi: 10.1056/NEJMoa2501796. Epub 2025 May 31. PubMed 40454641 ↗
  • Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Sunpaweravong P, Musolino A, Li H, Zhang Q, Nowecki Z, Leung R, Thanopoulou E, Shankar N, Lei G, Stout TJ, Hutchinson KE, Schutzman JL, Song C, Jhaveri KL. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024 Oct 31;391(17):1584-1596. doi: 10.1056/NEJMoa2404625. PubMed 39476340 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Sep 2023, 44 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 56 phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 9, 2019
StartActual
Jan 29, 2020
Primary completionActual
Sep 29, 2023
CompletionEst.
Nov 15, 2027
Results first posted
Oct 9, 2024
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04191499
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 9, 2019
Start date
Jan 29, 2020
Primary completion
Sep 29, 2023
Completion
Nov 15, 2027 (estimated)
Results posted
Oct 9, 2024
Last update
Sep 11, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inavolisib

Start the discussion